Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

Next-Generation Biologics and Biosimilars Market to Hit 251.13 billion Dollars by 2033 - Strategic Revenue Insights (SRI) ...

Shares of Q32 jumped 78% in premarket trading, to $3.90, while Akebia's stock was roughly flat. Akebia said the product candidate, AKB-097, is believed to have applicability across a wide range of ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

An announcement from Q32 Bio ( ($QTTB) ) is now available. On November 28, 2025, Q32 Bio Inc. entered into an Asset Purchase Agreement with Akebia ...

The Center supports clients across the development and manufacturing of biologics, RNA therapeutics, vaccines, and cell and gene therapies.

Treating cancer with medicines that tightly attach to their targets via covalent bonds is not a new concept in drug discovery, but it is picking up pace. Some companies are trying to improve this ...

Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced that it has successfully completed a Type C ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, ...

YD Bio Limited ('YD Bio” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer ...